Cargando…
Epoxylathyrane Derivatives as MDR-Selective Compounds for Disabling Multidrug Resistance in Cancer
BACKGROUND: Multidrug resistance (MDR) has been regarded as one of the major hurdles for the successful outcome of cancer chemotherapy. The collateral sensitivity (CS) effect is one the most auspicious anti-MDR strategies. Epoxylathyrane derivatives 1–16 were obtained by derivatization of the macroc...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226783/ https://www.ncbi.nlm.nih.gov/pubmed/32457612 http://dx.doi.org/10.3389/fphar.2020.00599 |
_version_ | 1783534360953094144 |
---|---|
author | Reis, Mariana Alves Matos, Ana M. Duarte, Noélia Ahmed, Omar Bauomy Ferreira, Ricardo J. Lage, Hermann Ferreira, Maria-José U. |
author_facet | Reis, Mariana Alves Matos, Ana M. Duarte, Noélia Ahmed, Omar Bauomy Ferreira, Ricardo J. Lage, Hermann Ferreira, Maria-José U. |
author_sort | Reis, Mariana Alves |
collection | PubMed |
description | BACKGROUND: Multidrug resistance (MDR) has been regarded as one of the major hurdles for the successful outcome of cancer chemotherapy. The collateral sensitivity (CS) effect is one the most auspicious anti-MDR strategies. Epoxylathyrane derivatives 1–16 were obtained by derivatization of the macrocyclic diterpene epoxyboetirane A (17), a lathyrane-type macrocyclic diterpene isolated from Euphorbia boetica. Some of these compounds were found to strongly modulate P-glycoprotein (P-gp/ABCB1) efflux. PURPOSE: The main goal was to develop lathyrane-type macrocyclic diterpenes with improved MDR-modifying activity, by targeting more than one anti-MDR mechanism. STUDY DESIGN/METHODS: In this study, the potential CS effect of compounds 1–16 was evaluated against gastric (EPG85-257), pancreatic (EPP85-181), and colon (HT-29) human cancer cells and their drug-resistant counterparts, respectively selected against mitoxantrone (EPG85-257RNOV; EPP85-181RNOV; HT-RNOV) or daunorubicin (EPG85-257RDB; EPP85-181RDB; HT-RDB). The most promising compounds (8, 15, and 16) were investigated as apoptosis inducers, using the assays annexin V/PI and active caspase-3. RESULTS: The compounds were more effective against the resistant gastric cell lines, being the CS effect more significant in EPG85-257RDB cells. Taking together the IC(50) values and the CS effect, compounds 8, 15, and 16 exhibited the best results. Epoxyboetirane P (8), with the strongest MDR-selective antiproliferative activity against gastric carcinoma EPG85-257RDB cells (IC(50) of 0.72 µM), being 10-fold more active against this resistant subline than in sensitive gastric carcinoma cells. The CS effect elicited by compounds 15 and 16 appeared to be by inducing apoptosis via caspase-3 activation. Structure-activity relationships of the compounds were additionally obtained through regression models to clarify the structural determinants associated to the CS effect. CONCLUSIONS: This study reinforces the importance of lathyrane-type diterpenes as lead molecules for the research of MDR-modifying agents. |
format | Online Article Text |
id | pubmed-7226783 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-72267832020-05-25 Epoxylathyrane Derivatives as MDR-Selective Compounds for Disabling Multidrug Resistance in Cancer Reis, Mariana Alves Matos, Ana M. Duarte, Noélia Ahmed, Omar Bauomy Ferreira, Ricardo J. Lage, Hermann Ferreira, Maria-José U. Front Pharmacol Pharmacology BACKGROUND: Multidrug resistance (MDR) has been regarded as one of the major hurdles for the successful outcome of cancer chemotherapy. The collateral sensitivity (CS) effect is one the most auspicious anti-MDR strategies. Epoxylathyrane derivatives 1–16 were obtained by derivatization of the macrocyclic diterpene epoxyboetirane A (17), a lathyrane-type macrocyclic diterpene isolated from Euphorbia boetica. Some of these compounds were found to strongly modulate P-glycoprotein (P-gp/ABCB1) efflux. PURPOSE: The main goal was to develop lathyrane-type macrocyclic diterpenes with improved MDR-modifying activity, by targeting more than one anti-MDR mechanism. STUDY DESIGN/METHODS: In this study, the potential CS effect of compounds 1–16 was evaluated against gastric (EPG85-257), pancreatic (EPP85-181), and colon (HT-29) human cancer cells and their drug-resistant counterparts, respectively selected against mitoxantrone (EPG85-257RNOV; EPP85-181RNOV; HT-RNOV) or daunorubicin (EPG85-257RDB; EPP85-181RDB; HT-RDB). The most promising compounds (8, 15, and 16) were investigated as apoptosis inducers, using the assays annexin V/PI and active caspase-3. RESULTS: The compounds were more effective against the resistant gastric cell lines, being the CS effect more significant in EPG85-257RDB cells. Taking together the IC(50) values and the CS effect, compounds 8, 15, and 16 exhibited the best results. Epoxyboetirane P (8), with the strongest MDR-selective antiproliferative activity against gastric carcinoma EPG85-257RDB cells (IC(50) of 0.72 µM), being 10-fold more active against this resistant subline than in sensitive gastric carcinoma cells. The CS effect elicited by compounds 15 and 16 appeared to be by inducing apoptosis via caspase-3 activation. Structure-activity relationships of the compounds were additionally obtained through regression models to clarify the structural determinants associated to the CS effect. CONCLUSIONS: This study reinforces the importance of lathyrane-type diterpenes as lead molecules for the research of MDR-modifying agents. Frontiers Media S.A. 2020-05-08 /pmc/articles/PMC7226783/ /pubmed/32457612 http://dx.doi.org/10.3389/fphar.2020.00599 Text en Copyright © 2020 Reis, Matos, Duarte, Ahmed, Ferreira, Lage and Ferreira http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Reis, Mariana Alves Matos, Ana M. Duarte, Noélia Ahmed, Omar Bauomy Ferreira, Ricardo J. Lage, Hermann Ferreira, Maria-José U. Epoxylathyrane Derivatives as MDR-Selective Compounds for Disabling Multidrug Resistance in Cancer |
title | Epoxylathyrane Derivatives as MDR-Selective Compounds for Disabling Multidrug Resistance in Cancer |
title_full | Epoxylathyrane Derivatives as MDR-Selective Compounds for Disabling Multidrug Resistance in Cancer |
title_fullStr | Epoxylathyrane Derivatives as MDR-Selective Compounds for Disabling Multidrug Resistance in Cancer |
title_full_unstemmed | Epoxylathyrane Derivatives as MDR-Selective Compounds for Disabling Multidrug Resistance in Cancer |
title_short | Epoxylathyrane Derivatives as MDR-Selective Compounds for Disabling Multidrug Resistance in Cancer |
title_sort | epoxylathyrane derivatives as mdr-selective compounds for disabling multidrug resistance in cancer |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226783/ https://www.ncbi.nlm.nih.gov/pubmed/32457612 http://dx.doi.org/10.3389/fphar.2020.00599 |
work_keys_str_mv | AT reismarianaalves epoxylathyranederivativesasmdrselectivecompoundsfordisablingmultidrugresistanceincancer AT matosanam epoxylathyranederivativesasmdrselectivecompoundsfordisablingmultidrugresistanceincancer AT duartenoelia epoxylathyranederivativesasmdrselectivecompoundsfordisablingmultidrugresistanceincancer AT ahmedomarbauomy epoxylathyranederivativesasmdrselectivecompoundsfordisablingmultidrugresistanceincancer AT ferreiraricardoj epoxylathyranederivativesasmdrselectivecompoundsfordisablingmultidrugresistanceincancer AT lagehermann epoxylathyranederivativesasmdrselectivecompoundsfordisablingmultidrugresistanceincancer AT ferreiramariajoseu epoxylathyranederivativesasmdrselectivecompoundsfordisablingmultidrugresistanceincancer |